Mersana Therapeutics (MRSN) Expected to Announce Quarterly Earnings on Wednesday

Posted by Wayne Rhoads on Feb 24th, 2025

Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Mersana Therapeutics to post earnings of ($0.16) per share and revenue of $7.71 million for the quarter.

Mersana Therapeutics Stock Performance

MRSN opened at $0.53 on Monday. The firm has a market cap of $65.87 million, a P/E ratio of -0.87 and a beta of 1.40. Mersana Therapeutics has a 52-week low of $0.49 and a 52-week high of $6.28. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. The business’s fifty day moving average is $0.97 and its 200-day moving average is $1.60.

Analysts Set New Price Targets

Several analysts recently weighed in on MRSN shares. Wedbush restated an “outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Mersana Therapeutics in a research report on Friday, January 10th. Citigroup assumed coverage on Mersana Therapeutics in a research note on Friday, November 15th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, William Blair started coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $5.57.

View Our Latest Research Report on MRSN

About Mersana Therapeutics

(Get Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.